Literature DB >> 33485437

South Africa responds to new SARS-CoV-2 variant.

Munyaradzi Makoni.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33485437      PMCID: PMC7825846          DOI: 10.1016/S0140-6736(21)00144-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
Land borders have been closed and restrictions continue as a new variant stresses the health system. Munyaradzi Makoni reports. On Jan 11, 2021, South Africa closed 20 land border posts for general entry and departure until Feb 15, as COVID-19 cases surged because of the spread of a new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The move comes amid rising infections and deaths, especially as people return to work following the festive season. As a regional economic hub, South Africa attracts many migrants. Land border crossings have been hugely congested, particularly the busiest six: Beitbridge, Lebombo, Maseru Bridge, Oshoek, Ficksburg, and Kopfontein. Many people were exposed to COVID-19 infections as they waited many hours to cross the border. The UN Food and Agriculture Organization (FAO) has warned that the restrictions have particularly affected landlocked Lesotho, which imports the bulk of its goods and services from South Africa. It says that more than 580 000 people out of a population of 2·2 million are food insecure. “It has been difficult to ensure that the health requirements for entry into South Africa are met, with many people arriving without proof of COVID-19 tests”, said South African President Cyril Ramaphosa, in a televised national address. In South Africa, COVID-19 has claimed the lives of more than 37 000 people and more than 1·3 million COVID-19 cases have been recorded in the past 10 months. More than 148 000 people have been admitted to hospital with the disease. “The pandemic in our country is now at its most devastating. The number of new infections, hospital admissions, and deaths is higher now than it has ever been since the first case was recorded in our country in March, 2020”, said Ramaphosa. A new SARS-CoV-2 variant (501Y. V2) that was first discovered in South Africa has raised concern over new infections. In November, 2020, clinicians alerted South African scientists about a rapid increase in the number of people with COVID-19 in the Nelson Mandela Bay region in the Eastern Cape province, leading to the identification of a new variant of the virus in South Africa. Since Jan 1, the country has recorded nearly 190 000 new SARS-CoV-2 infections and more than 4600 COVID-19 deaths so far this year. The WHO Regional Office for Africa says that the new variant circulating in the region has been detected in Botswana, The Gambia, and Zambia, but preliminary studies show no evidence that this variant causes more severe disease. “We do know that this new variant of the virus spreads much faster than the earlier variants. This explains the fact that many more people have become infected in a far shorter space of time”, said Ramaphosa. The spread of the new variant puts more pressure on the health system because the number of cases increases so rapidly and the hospitals get full more quickly, but the transmission of the new variant can be prevented using exactly the same measures that we have been using for protection against the virus all along, said Ramaphosa. “[The situation is] terrible, how more transmission [ends] up with much more deaths, even if the variant is not more pathogenic”, said Tulio de Oliveira, director of the KwaZulu-Natal Research Innovation and Sequencing Platform and principal investigator of the Network for Genomic Surveillance in South Africa in a post on Twitter. “People need to realise that when hospitals get overwhelmed, deaths increase very fast”, he added. GISAID, a global initiative that promotes sharing of sequence data, says that new variants of SARS-CoV-2 have also been reported in Brazil, France, Australia, Germany, Switzerland, Japan, Sweden, South Korea, Finland, Ireland, the Netherlands, and the UK. To curb the spread of the second wave, South Africa has maintained restrictions such as the ban on sale and movement of alcohol and a limit on the number of people allowed to attend public gatherings. Most indoor and outdoor gatherings remain banned, including religious and political events, but not funerals—despite evidence for an increased risk of transmission at these events—which are limited to 50 people and strict protocols including physical distancing, hand sanitising, and mask wearing being observed. To date, South Africa has secured 20 million doses of vaccine from different manufacturers, to be delivered mainly in the first half of 2021. Earlier in January, Health Minister Zweli Mkhize announced that South Africa would be receiving 1 million doses in January and 500 000 doses in February of the AstraZeneca-Oxford vaccine from the Serum Institute of India. The priority for vaccination would be front-line health workers. “We will undertake a massive programme of COVID-19 vaccination”, Ramaphosa said. South Africa is estimated to need 67% of the population (40 million people) vaccinated to achieve herd immunity to reduce spread, he said.
  26 in total

Review 1.  Evolutionary Traits and Genomic Surveillance of SARS-CoV-2 in South America.

Authors:  Pablo A Ortiz-Pineda; Carlos H Sierra-Torres
Journal:  Glob Health Epidemiol Genom       Date:  2022-05-18

Review 2.  Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures.

Authors:  Wenxia Shao; Weiying Zhang; Xiang Fang; Daojun Yu; Xianjun Wang
Journal:  J Microbiol Immunol Infect       Date:  2022-04-26       Impact factor: 10.273

3.  SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.

Authors:  Qianqian Li; Jianhui Nie; Jiajing Wu; Li Zhang; Ruxia Ding; Haixin Wang; Yue Zhang; Tao Li; Shuo Liu; Mengyi Zhang; Chenyan Zhao; Huan Liu; Lingling Nie; Haiyang Qin; Meng Wang; Qiong Lu; Xiaoyu Li; Junkai Liu; Haoyu Liang; Yi Shi; Yuelei Shen; Liangzhi Xie; Linqi Zhang; Xiaowang Qu; Wenbo Xu; Weijin Huang; Youchun Wang
Journal:  Cell       Date:  2021-02-23       Impact factor: 41.582

4.  Public Oral Health Care During COVID-19: Time for Reflection and Action.

Authors:  Shenuka Singh
Journal:  Front Med (Lausanne)       Date:  2021-03-17

5.  Genomic Analysis and Lineage Identification of SARS-CoV-2 Strains in Migrants Accessing Europe Through the Libyan Route.

Authors:  Fabio Tramuto; Stefano Reale; Alessandra Lo Presti; Francesco Vitale; Claudio Pulvirenti; Giovanni Rezza; Fabrizio Vitale; Giuseppa Purpari; Carmelo Massimo Maida; Salvatore Zichichi; Silvia Scibetta; Walter Mazzucco; Paola Stefanelli
Journal:  Front Public Health       Date:  2021-04-15

6.  Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg-a report from the AGMT COVID-19 Registry.

Authors:  Florian Huemer; Gabriel Rinnerthaler; Benedikt Jörg; Patrick Morre; Birgit Stegbuchner; Elisabeth Proksch; Stefanie Fleimisch; Hannes Oberkofler; Iris Kremser; Richard Greil; Alexander Egle
Journal:  Geroscience       Date:  2021-04-10       Impact factor: 7.713

7.  The time to offer treatments for COVID-19.

Authors:  Binh T Ngo; Paul Marik; Pierre Kory; Leland Shapiro; Raphael Thomadsen; Jose Iglesias; Stephen Ditmore; Marc Rendell; Joseph Varon; Michael Dubé; Neha Nanda; Gino In; Daniel Arkfeld; Preet Chaudhary; Vito M Campese; Diana L Hanna; David E Sawcer; Glenn Ehresmann; David Peng; Miroslaw Smogorewski; April Armstrong; Rajkumar Dasgupta; Fred Sattler; Denise Brennan-Rieder; Cristina Mussini; Oriol Mitja; Vicente Soriano; Nicolas Peschanski; Gilles Hayem; Marco Confalonieri; Maria Carmela Piccirillo; Antonio Lobo-Ferreira; Iraldo Bello Rivero; Mika Turkia; Eivind H Vinjevoll; Daniel Griffin; Ivan Fn Hung
Journal:  Expert Opin Investig Drugs       Date:  2021-04-23       Impact factor: 6.206

8.  Replication Kinetics of B.1.351 and B.1.1.7 SARS-CoV-2 Variants of Concern Including Assessment of a B.1.1.7 Mutant Carrying a Defective ORF7a Gene.

Authors:  Alyssa T Pyke; Neelima Nair; Andrew F van den Hurk; Peter Burtonclay; Son Nguyen; Jean Barcelon; Carol Kistler; Sanmarié Schlebusch; Jamie McMahon; Frederick Moore
Journal:  Viruses       Date:  2021-06-07       Impact factor: 5.048

9.  A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.

Authors:  Maria Pino; Talha Abid; Susan Pereira Ribeiro; Venkata Viswanadh Edara; Katharine Floyd; Justin C Smith; Muhammad Bilal Latif; Gabriela Pacheco-Sanchez; Debashis Dutta; Shelly Wang; Sanjeev Gumber; Shannon Kirejczyk; Joyce Cohen; Rachelle L Stammen; Sherrie M Jean; Jennifer S Wood; Fawn Connor-Stroud; Jeroen Pollet; Wen-Hsiang Chen; Junfei Wei; Bin Zhan; Jungsoon Lee; Zhuyun Liu; Ulrich Strych; Neeta Shenvi; Kirk Easley; Daniela Weiskopf; Alessandro Sette; Justin Pollara; Dieter Mielke; Hongmei Gao; Nathan Eisel; Celia C LaBranche; Xiaoying Shen; Guido Ferrari; Georgia D Tomaras; David C Montefiori; Rafick P Sekaly; Thomas H Vanderford; Mark A Tomai; Christopher B Fox; Mehul S Suthar; Pamela A Kozlowski; Peter J Hotez; Mirko Paiardini; Maria Elena Bottazzi; Sudhir Pai Kasturi
Journal:  Sci Immunol       Date:  2021-07-15

Review 10.  SARS-CoV-2 Genetic Variability and Non-Specific Immunity Associated with the Use of Different BCG Strains-A Molecular and Clinical Approach.

Authors:  Jakub Kulus; Magdalena Kulus; Katarzyna Stefańska; Jarosław Sobolewski; Hanna Piotrowska-Kempisty; Paul Mozdziak; Bartosz Kempisty
Journal:  Vaccines (Basel)       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.